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Objective: Genetic factors are important in the aetiology of hip osteoarthritis (OA), but studies are limited
by cross-sectional design and poor association with clinically important disease. Identifying cohorts with
progressive OA will facilitate development of OA biomarkers. Using a middle-aged cohort with genetic
predisposition to hip OA and a control group, we compared the prevalence of clinical and radiographic
hip OA and incidence of progression over 5 years.
Design: 123 individuals (mean age 52 years) with a family history of total hip arthroplasty (THA)
(‘sibkids’) were compared with 80 (mean age 54 years) controls. The prevalence of radiographic OA
[scored according to Kellgren & Lawrence (K&L)], clinical features, and incidence of clinical progression
over a 5-year period were compared. A multivariate logistic regression model was used to adjust for
confounders.
Results: Sibkids had odds ratios (ORs) of 2.7 [95% conﬁdence interval (CI) 1.1e6.3, P ¼ 0.02] for hip OA
(K&L grade 2), 3.4 (1.4e8.4, P ¼ 0.008) for clinical signs, and 2.1 (0.8e5.8, P ¼ 0.14) for signs and
symptoms. Over 5 years, sibkids had ORs of 4.7 (1.7e13.2, P ¼ 0.003) for the development of signs, and
3.2 (1.0e10.3, P ¼ 0.047) for the development of signs and symptoms.
Discussion: Compared to a control group and after adjustment for confounders, individuals with genetic
predisposition to end-stage hip OA have higher prevalence of OA, clinical features, and progression. In
addition to structural degeneration, the inherited risk may include predisposition to pain. Genetically-
loaded cohorts are useful to develop hip OA biomarkers, as they develop progressive disease at
a young age.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Hip osteoarthritis (OA) is a major health burden and the demand
for total hip arthroplasty (THA) for end-stage OA is anticipated to
increase, as people live longer and have higher functional expec-
tations1. In spite of its clinical heterogeneity and multifactorial
nature, its aetiology has a signiﬁcant genetic basis2. The increased
risk of hip OA to siblings of patients with the disease is well
established3e6, and this risk is also passed on to their offspring7.
Classic twin studies suggest that hip OA is highly heritable with
a genetic contribution of approximately 60% in women4,8. Linkage
studies have identiﬁed regions of chromosomes 2, 4, 6, 7, 11, 16, 19,to: T.C.B. Pollard, Nufﬁeld
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s Research Society International. Pand the X chromosome as harbouring important loci involved in
the heritability of OA2. It is suggested that the majority of loci
identiﬁed encode for regulatory rather than structural
proteins2,9,10, and that at least ﬁve biological pathways may be
implicated in the pathogenesis of hip OA, including inﬂammatory
cytokine, BMP, and wingless (wnt) pathways2,11. However, further
association studies are required to conﬁrm the validity of these
observations2.
The ultimate goal of the study of genetic factors in hip OA is to
allow the early identiﬁcation of “at risk” patients and allow the
identiﬁcation of novel therapeutic interventions that will prevent
the condition or the pain it causes, or at least limit progression to
end-stage disease requiring joint replacement. Whilst genetic
modiﬁcation may become realistic in the future, recent develop-
ments in surgical practice, in particular the treatment of femo-
roacetabular impingement, have opened potential opportunities
for limiting disease progression. It is clear that for such intervention
to be effective, it needs to occur before signiﬁcant cartilage damage
has occurred12,13. Furthermore, reliable outcome measures, orublished by Elsevier Ltd. All rights reserved.
T.C.B. Pollard et al. / Osteoarthritis and Cartilage 20 (2012) 368e375 369biomarkers, are required to assess the effectiveness of potential
disease-modifying treatments in clinical trials. Finding suitable
cohorts to validate such biomarkers is problematic, although
examples related speciﬁcally to hip OA include the Rotterdam14,
GARP15, Chingford16, and CHECK17 cohorts. The ideal group would
likely consist of individuals, who are at an early stage of disease but
are anticipated to progress to clinically signiﬁcant disease.
Although there is ample evidence for a genetic predisposition to
radiographic hip OA4,8, the evidence for an inherited predisposition
to progressive OA, is more limited. In a cross-sectional study,
Chitnavis et al.3 demonstrated a sibling relative risk of 1.9 for THA
for OA. Botha-Scheepers et al.15 calculated odds ratios (ORs) of 2.2
and 3.6 respectively for progressive joint space narrowing and
osteophyte formation in the hips of siblings of probands with
radiographic and symptomatic hip OA over a 2-year period. The
subjects in this study had OA at multiple sites, and it was not clear
how many of those progressing radiographically also had clinical
features. Furthermore, the ORs for progression in the siblings were
calculated from the progression status of the probands, and there
was no control group without a genetic predisposition to OA in the
study. Van Meurs et al. discovered that amongst individuals with
hip OA, a functional polymorphism in the catechol-O-
methyltransferase gene (158Met allele) was associated with
increased pain, with an OR of 4.918. Whilst this ﬁnding should be
interpretedwith some caution given the broad conﬁdence intervals
(CIs) (1.6e14.8), it is nevertheless possible that constructing
cohorts with a genetic predisposition to OA may be a fruitful
method to enable focussed investigation of particular genetic
markers associated with progression and symptoms.
The aim of this study was to establish whether middle-aged
subjects with a family history of THA for end-stage hip OA were
more likely to demonstrate clinical and radiographic features of hip
OA than a control group, and have evidence of signiﬁcant clinical
progression over a 5-year period.
Methods
Cohorts
The subjects for this study were enrolled from a prospective
longitudinal study7 of a cohort considered to be at risk for the
development of hip OA, and their spouse controls (Fig. 1). The study
had institutional review board approval and all subjects consented
to participation. The background for the development of this cohort
was a sibling study of THA for end-stage OA performed by Chitnavis
et al.3 at our institution. From a consecutive series of patients
undergoing THA for idiopathic OA, the prevalence of THA in their
siblings was established and compared with a spouse control
group. This study conﬁrmed a genetic predisposition to the disease
with a relative risk estimate of 1.863. Spencer et al.7 examined the
offspring of families from the Chitnavis3 study with at least two
female siblings who had undergone THA. These offspring were
termed ‘sibkids’. The reason for choosing female sibling pairs was
because of the observation of shared genetic heritability between
female patients with Heberden’s nodes and hip OA19,20. Exclusion
criteria for enrolment included signiﬁcant trauma (hip injury
requiring consultation with General Practitioner or Emergency
department), any history of predisposing factors to hip OA, such as
developmental dysplasia, slipped capital femoral epiphysis, and
Perthes disease. No cases were excluded on these grounds. The
reason for the study by Spencer et al.7 was to identify if the OA risk
to the sibkids was apparent in early middle-age, when it may be
possible to observe progression over a number of decades, or
potentially validate OA biomarkers. 145 sibkids from 40 families
were recruited at baseline7 (see Fig. 1), together with their 119spouse controls. Advice regarding sample size for familial aggre-
gation studies was received from a medical geneticist. The current
study aimed to revisit the sibkid cohort and their spouses 5 years
after the baseline visit. The recruitment of the spouses as controls
enables comparison with a non-related group with similar envi-
ronmental exposure.
Clinical assessment
All subjects underwent clinical and radiographic assessment in
a dedicated research clinic. Clinical assessment was performed by
a single experienced orthopaedic fellow (TCBP). A proforma,
completed by a research nurse, was used to document the ﬁndings
in a standardised manner. Height and weight were recorded in
order to calculate body mass index (BMI). All subjects were asked
whether they had had surgery on either hip, and if they had
experienced any groin pain or clicking on either side in the last
2 years necessitating investigation or treatment. The Oxford Hip
(OHS)21, Western Ontario and McMasters University Osteoarthritis
index (WOMAC)22, and Non-Arthritic Hip23 scores (NAHS) were
completed for each hip. A routine examination of the hips was
performed and the presence of irritability on passive movement
(deﬁned as groin pain on hip ﬂexion, or on rotation at 90 degrees of
ﬂexion) or a positive anterior impingement sign24 (groin painwhen
the hip is ﬂexed to 90 degrees, adducted 20 degrees, then internally
rotated), recorded as binary outcomes. Because the orthopaedic
fellow that performed the clinical assessment also arranged the
clinic appointments, it was not possible to blind him to the
participant’s sibkid or spouse status; however the clinical assess-
ment was observed and documented independently by a research
nurse, and was performed before the radiographs were obtained.
Radiographic scoring was then performed blind to the clinical
assessment after an interval of at least 4 weeks.
Radiographic assessment
At the baseline assessment, radiographs of the hips were only
obtained if the participant had symptoms or clinical signs as
described above. 58 sibkids and eight controls had radiographs at
baseline. In the current 5-year follow-up, all participants underwent
a standardised radiographic assessment to identify features of OA.
Radiographic technique
A supine Anteroposterior (AP) pelvis radiograph was taken with
a 15 degree wedge placed beneath the femoral condyles of each leg
to ensure that the recommended internal rotation of each hip was
achieved, and the X-ray beam centred in the midline and on the
point midway between the superior border of the pubic symphysis
and a line drawn connecting the anterior superior iliac spines25,26.
A 20 mm calibration ball was secured to the skin overlying the
greater trochanter. In order to avoid rotated anteroposterior radio-
graphs, the radiographer repeated the radiograph if necessary to
ensure that the obturator foramen index27 was within 0.7e1.428.
Grading of OA
All radiographs were scored by consensus29,30 opinion of two
experienced readers (a Consultant Musculoskeletal Radiologist,
EGM, and an Orthopaedic Fellow, TCBP). Images were blinded for
patient characteristics. Osteophytosis was graded using the
Osteoarthritis Research Society International (OARSI) atlas31. The
minimum joint space width was recorded in each hip. Joint space
narrowing was deﬁned as a minimum joint spacewidth of less than
2.50 mm32,33 in males, and of less than 2.20 mm in females34.
Fig. 1. CONSORT ﬂow diagram to illustrate construction of cohorts.
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nication System (PACS, 2004, GE Healthcare UK Ltd, Little Chalfont,
Bucks, UK) digital images as TIFF ﬁles. A custom-designed validated
software program (HipMorf) in Matlab version R2007a (The
Mathworks Inc, Natick, Massachusetts) was used to measure the
minimum joint space width16,35. This program automatically cali-
brated distance for each hip to account for variable magniﬁcation
using the projected calibration marker ball. An overall OA grade
was assigned according to the principles of the Kellgren & Lawrence
(K&L) system30, whereby grade 0 is a normal minimum joint space
width and no osteophytosis, grade 1 disease (possible OA) is
deﬁned as osteophytosis (grade 1 or above at any site31) but no joint
space narrowing, and grade 2 (deﬁnite OA) deﬁned with joint space
narrowing (according to the thresholds of 2.50 mm and 2.20 mm).
Grades 3 and 4 were applied to hips with more severe joint space
narrowing, with arbitrary thresholds of <2.0 mm for grade 3 and
<1.0 mm or previous THA for grade 4 OA.The repeatability for the minimum joint space width and
osteophyte grading31, depicted by the intraclass correlation coefﬁ-
cient (ICC) and Kappa statistics respectively, was 0.87 for the
minimum joint space width and 0.91 (superior femoral), 0.83
(inferior femoral), 0.75 (superior acetabular), and 0.80 (inferior
acetabular) for the osteophyte scores, respectively. The repeat-
ability was based on the repeat readings of a random sample of 20
radiographs, which were selected throughout the period of
observation.
Clinical assessment of progression
In the study by Spencer et al.7, the baseline clinical assessment
was identical to that in this study, however patient-reported
outcome scores such as the Oxford Hip Score, were not
completed. Clinical progression was therefore determined by
comparison of the presence of signs and symptoms at baseline and
Table I
Demographics of the sibkid and control cohorts
Variable Sibkids (n ¼ 123) Controls (n ¼ 80) P value*
Mean age (SD) 52.3 (8.1) 54.1 (9.0) 0.15
Gender, number (%)
Male 62 (50%) 39 (49%) 0.82
Female 61 (50%) 41 (51%)
Mean BMI (SD) 25.8 (4.2) 25.8 (4.6) 0.99
* A two-sample t-test is used for continuous variables and a chi-squared test for
categorical variables.
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possible biases related to reporting of symptoms perceived to relate
to the hip, in the current study and for the statistical analyses,
symptoms of hip pain were only considered as signiﬁcant if
accompanied by supportive signs on examination. Participants
were thus classiﬁed into three categories: normal (negative
examination); positive signs (positive examination, no symptoms);
positive signs and symptoms (positive examination, with symp-
toms). Clinical progression from baseline was deﬁned as changing
categories from normal to positive signs  symptoms, or from
positive signs to positive signs and symptoms.
Outcomes and statistical analysis
There were two main outcome variables:
(1) The prevalence of OA at the 5-year visit: This was measured by
(1) radiographic assessment according to whether or not
a patient has K&L grade 2 or more (2) clinical assessment of
whether or not a patient has clinical signs and symptoms.
(2) Progression of OA between the baseline and 5-year visit: As
baseline radiographs were not available for all subjects this
could only be measured according to clinical assessment,
deﬁned as changing categories from normal to positive signs 
symptoms, or from positive signs to positive signs and
symptoms.
The primary comparison of interest was subjects with a family
history of THA for end-stage hip OA compared to spouse controls
(sibkid versus control). Age, sex and BMI were treated as potential
confounding variables to control for in the analysis. Where clinical
features were used to deﬁne outcomes, deﬁnite OA (K&L grade 2)
at the 5-year visit was adjusted for as an additional confounder, as
a binary variable.
Each subject had two measures of the outcome (left and right
hips). All the outcome variables were binary variables (Yes/No). A
Generalized Estimating Equations (GEE) population averaged
logistic regression model, adjusting for clustering of hips, was used
to describe the association of the predictor (sibkid versus control)
with each outcome separately, adjusting for confounders. Because
of the strong association of the outcomes with each other,Table II
GEE population averaged logistic regression model describing the association of cohort (
Outcome Primary predictor Yes
n hips (%)
No
n hips (%
Hip OA K&L grade 2 Sibkid
control
36 (15)
12 (8)
210 (85)
148 (92)
Signs Sibkid
control
38 (15)
8 (5)
208 (85)
152 (95)
Signs and symptoms Sibkid
control
21 (9)
6 (4)
225 (91)
154 (96)
* Multivariable model adjusted for clustering of hips, age, sex and BMI.adjustment for multiple comparisons was not made36. A number of
sibkids did not have spouse controls in the study, thus in order to
account for possible ensuing bias, a sensitivity analysis was per-
formed using only the sibkid and spouse pairs in the cohort.
Interobserver reproducibility for the assessment of clinical signs
(positive or negative, Kappa statistic) was calculated from
a subgroup of 20 subjects (40 hips), who were also examined by
a second observer. All statistical analyses were performed using
Stata version 11.1 (Stata, College Station, Tx).
Results
Cohort demographics
123 sibkids, from 35 families, and 80 spouse controls from the
original cohorts7 were reviewed. Demographics for the two groups
are shown in Table I.
Loss to follow-up
The mean follow-up was 5.3 years. From the original cohorts7,
22 sibkids and 39 controls were unavailable to attend for review. Of
the 22 sibkids, baseline assessment identiﬁed two with bilateral
K&L grade 1 hip OA, and one had severe bilateral hip OA (right hip
treated with hip resurfacing, grade 3 on the left side). Four further
sibkids had reported mild symptoms but had no radiographic
evidence of hip OA. From the 39 controls that were unable to
attend, at baseline only one had reported mild symptoms but had
no radiographic evidence of hip OA. The remaining controls had no
clinical evidence of hip OA, and radiographs were not obtained.
Comparison of the sibkids lost to follow-up (n ¼ 22) with those
included in the present study (n ¼ 123) indicated that the mean
ages were similar [54.7 years (standard deviation (SD) 10.5), and
52.3 years (8.1) respectively, P ¼ 0.22]. Although the proportion of
females in the loss to follow-up group was proportionately greater
(16 of 22 lost were female), overall there was no signiﬁcant
difference in gender proportions between the original and current
sibkid cohorts (P ¼ 0.62). Similarly, in the controls the mean age of
those lost to follow-up was similar to those included [53.8 (10.6)
years and 54.1 (9.0) years respectively, P ¼ 0.89]. Although the
proportion of females in the loss to follow-up group was pro-
portionately less (15 of 39 lost were female), the gender propor-
tions at the two time-points were similar (P ¼ 0.57).
Current prevalence of OA at 5 years
Radiographic OA
Table II and Fig. 2 show the numbers of hips with deﬁnite
radiographic hip OA. Population averaged (GEE) logistic regression
analysis, adjusted for age, BMI, and gender, indicated that the OR for
radiographic hip OA in the sibkids versus controls was 2.68 times
higher (95% CI 1.14e6.30, P ¼ 0.02). In the sibkid group, of the 36sibkid/control) with prevalence of OA at 5 years, in the 123 sibkids and 80 controls
)
Univariable Multivariable*
OR P Val OR P Val
2.11 (0.93, 4.81) 0.074 2.68 (1.14, 6.30) 0.024
3.47 (1.40, 8.58) 0.007 3.38 (1.37, 8.35) 0.008
2.40 (0.90, 6.40) 0.082 2.13 (0.78, 5.76) 0.14
Fig. 2. Histogram showing the differences in prevalence of clinical features and OA in
the sibkids and spouses.
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four were grade 4. In the control group, of the 12 hips with deﬁnite
OA, eight were grade 2 and four were grade 3. 75 sibkid hips (30.5%)
were K&L grade 1 compared to 51 hips (31.9%) in the control group.
Of the hips with deﬁnite OA, in both the sibkid and control groups,
half were accounted for by subjects with unilateral OA (18 sibkids
and six controls) and the remainder by subjects with bilateral OA
(nine sibkids and three controls).
Clinical features of OA
Based on the assessment of 20 subjects, the interobserver
reproducibility for the assessment of clinical signs was 0.76. 36
sibkid hips and six spouse control hips were symptomatic but did
not have clinical signs on examination and were therefore cat-
egorised as normal for the purposes of the analysis (Fig. 2). Table II
shows the numbers of hips with positive clinical signs on exami-
nation. Population averaged (GEE) logistic regression analysis,
adjusted for age, BMI, gender, and presence of radiographic hip OA,
indicated that the OR for the presence of signs in the sibkids versus
controls was 3.38 (95% CI 1.37e8.35, P ¼ 0.008). The 38 sibkid hips
with signs comprised 20 individuals with unilateral signs and nine
with bilateral signs. The eight control hips comprised six with
unilateral signs and one bilateral.
The numbers of hips with both positive clinical signs on
examination and hip symptoms are shown in Table II. Population
averaged (GEE) logistic regression analysis, adjusted for age, BMI,
gender, and presence of radiographic hip OA, indicated that the OR
for the presence of signs and symptoms in the sibkids versus
controls was 2.13 (95% CI 0.78e5.76, P ¼ 0.14). The 21 sibkid hips
with signs and symptoms comprised 15 individuals with unilateral
signs and symptoms and three with bilateral signs and symptoms.
The six control hips with signs and symptoms were all unilateral in
six individuals. The clinical scores amongst those with signs and
symptoms in the two groups were similar: the median OHS was 44
in the sibkids, and 45 in the controls; the median WOMAC was sixTable III
GEE population averaged logistic regressionmodel describing the association of cohort (si
sibkids and 80 controls
Outcome Primary predictor Yes
n hips (%)
Change in prevalence of signs Sibkid
control
36 (15)
6 (4)
Change in prevalence of signs and symptoms Sibkid
control
19 (8)
4 (3)
* Multivariable model adjusted for clustering of hips, age, sex, BMI and 5-year K&L grin the sibkids and seven in the controls; and the median NAHS was
87.5 in the sibkids and 85.6 in the controls.
10 sibkids and nine controls reported the regular use of anal-
gesics or anti-inﬂammatories. Of these, the majority (six sibkids
and seven controls) had no clinical signs or symptoms or radio-
graphic hip OA. One sibkid and one control had symptomatic
radiographic hip OA. Two sibkids and one control had radiographic
hip OA but no clinical features. Therefore the use of analgesics in
this small subgroup is very unlikely to have affected the overall
results.
Five-year clinical progression of OA
At baseline assessment, 54 sibkid and ﬁve control hips reported
symptoms without clinical signs. Two sibkid and two control hips
had signs, which were accompanied by symptoms in all four cases.
No sibkid or control hips regressed clinically over the 5-year period
(i.e., became ‘normal’ having previously had positive clinical signs,
or asymptomatic having previously reported symptoms).
The number of hips with new clinical signs on examination over
the 5-year period since baseline assessment is shown in Table III.
Population averaged (GEE) logistic regression analysis, adjusted for
age, BMI, gender, and presence of radiographic hip OA, indicated
that the OR for the development of signs in the sibkids versus
controls was 4.75 (95% CI 1.70e13.24, P ¼ 0.003).
The number of hips developing clinical signs and symptoms
over the same period is shown in Table III. Of these hips, 16 of the
sibkid and one of the control hips had symptoms but no signs at
baseline, with the remainder clinically normal at baseline.
Population averaged (GEE) logistic regression analysis, adjusted for
age, BMI, gender, and presence of radiographic hip OA, indicated
that the OR for the development of signs and symptoms in the
sibkids versus controls was 3.23 (95% CI 1.02e10.28, P ¼ 0.047).Sensitivity analysis
Repetition of the above outcome analyses using only sibkid and
spouse control pairs produced similar ORs with similar levels of
statistical signiﬁcance.Discussion
This study conﬁrmed that individuals with a strong family
history of hip OA are more likely to develop radiographic hip OA
compared with controls. Importantly, the prevalence of clinical
features was also higher in the sibkid group, indicating that the
radiographic differences are clinically signiﬁcant. Having adjusted
for the presence of radiographic OA, the OR for clinical signs was
signiﬁcantly greater in the sibkids conﬁrming the clinical signiﬁ-
cance and suggesting that in addition to structural degeneration,
the inherited riskmay bemanifest through a predisposition to pain.
Our ﬁndings support the notion that the genetic association with
hip OA is manifest both radiographically and clinically.bkid/control) with clinical progression of OA between baseline and 5 years, in the 123
No
n hips (%)
Univariable Multivariable*
OR P Val OR P Val
210 (85)
154 (96)
4.40 (1.58, 12.28) 0.005 4.75 (1.70, 13.24) 0.003
227 (92)
156 (97)
3.26 (1.05, 10.20) 0.042 3.23 (1.02, 10.28) 0.047
ade.
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factors in the aetiology of hip OA4,6,8. Most studies are cross-sectional
however, and many have focussed on the presence of radiographic
OA whilst not examining the association with clinical features4,6,8.
With regards to inherited susceptibility to clinical OA, a number of
studies report sibling risks for THA as a surrogate for severe clinical
disease3,5,37,38, but there are few examples of familial aggregative
studies of both clinical and radiological hip OA prior to end-stage
disease7,39. Furthermore, few studies have examined progression of
disease in a prospective fashion15. Clinically important OA requires
co-existing symptoms, yet radiographic OA does not correlate well
with symptoms, particularly in the early stages40e42. Therefore, the
most interesting group to study are those who are not only likely to
progress radiographically but also to develop clinical features early.
The sibkid cohort meets these criteria.
There are three possible explanations that may account for the
additional risk of clinical features in the sibkids, even after
adjusting for radiographic changes. Plain radiography was used to
assess the presence and progression of OA as recommended by
OARSI43. The development of pre-radiographic structural disease,
such as labral or early chondral damage, may have been occurring
in the sibkids and could be detected by a more sensitive imaging
method13,44e46. On-going follow-up will conﬁrm whether these
cases go on to develop radiographic OA. Alternatively, a predispo-
sition to inﬂammation or soft tissue change may account for the
difference and this could potentially be identiﬁed using alternative
biomarkers of early OA47. Finally, recent insights have highlighted
the importance of central pain processing in OA48. Genetic inﬂu-
ences seem likely to have an important role here49.
This study had a number of strengths and weaknesses. All
subjects had clinical and radiological screening of their hips,
whether symptomatic or not, allowing the prevalence of subclinical
radiographic OA and positive examination ﬁndings to be identiﬁed.
The cohort size was smaller than some sibling studies6, however
this reﬂects the unique sibkid study design, as the sibling study by
Chitnavis et al.3 on which our sibkid cohort was based included
1171 siblings, from which 40 sibling pairs with end-stage hip OA
were recruited whose offspring ultimately comprised the sibkid
cohort. The sibkid cohort was constructed from families treated
with THA and was therefore genetically loaded towards clinically
important OA rather than just radiographic changes. The reason for
choosing female sibling pairs was because of the observation of
shared genetic heritability between female patients with Heber-
den’s nodes and hip OA19,20. This may limit the extrapolation of
these data to inherited risk of hip OA in males. Loss to follow-up
was within acceptable limits for a follow-up study; amongst the
sibkids lost to follow-up were one subject with severe bilateral OA
and two with grade 1 OA. In the controls, none of the cases lost to
follow-up had evidence of OA at baseline. Therefore, the loss to
follow-up is unlikely to have explained our results. Although our
analysis accounted for some important potential confounders, data
regarding occupation and leisure activities was not recorded and
thus these factors not accounted for. Finally, different observers
performed the clinical assessments at baseline and current review.
The examination was standardised, both were trained and differ-
ences in orthopaedic surgeons’ sensitivity would be applied equally
to both sibkids and controls at each visit. Ideally, the assessor would
have been blinded to participant status; however this was not
practically possible for the clinical assessment, although this was
performed prior to radiography with the clinical examination
documented by a research nurse. In order to avoid potential biases
in the reporting of symptoms by individuals, particularly in the
sibkid group, only subjects who had signs as well as symptoms
were included in the statistical analysis. This method is based on
the assumption that clinical progression starts with signs beforesymptoms. In fact, the number of subjects reporting symptoms
without clinical signs was much higher in the sibkid group and
interestingly approximately one-third of those reporting symptoms
without signs at baseline progressed over 5 years. Potentially more
of these cases may develop signs over time.
In conclusion, this study has validated previous reports that
there is a strong genetic association with hip OA which is apparent
in middle-age. Unlike previous studies however, we have demon-
strated that it is also associated with clinically progressive disease.
Furthermore, clinical features were apparent in the sibkids prior to
radiographic changes. These ﬁndings suggest that a genetically-
loaded cohort may be an extremely useful group to utilise in
order to develop biomarkers of early hip OA, as they appear to
develop disease at a young age and are likely to progress clinically.
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